JP2012532107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532107A5 JP2012532107A5 JP2012517823A JP2012517823A JP2012532107A5 JP 2012532107 A5 JP2012532107 A5 JP 2012532107A5 JP 2012517823 A JP2012517823 A JP 2012517823A JP 2012517823 A JP2012517823 A JP 2012517823A JP 2012532107 A5 JP2012532107 A5 JP 2012532107A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- composition
- disease
- enantiomer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 14
- 208000002193 Pain Diseases 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 3
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 2
- 230000004907 flux Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- YNHVBNGRNNVEMD-UHFFFAOYSA-N 2-(bromomethyl)-5-(trifluoromethyl)furan Chemical compound FC(F)(F)C1=CC=C(CBr)O1 YNHVBNGRNNVEMD-UHFFFAOYSA-N 0.000 claims 1
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020844 Hyperthermia malignant Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 claims 1
- 208000026709 Liddle syndrome Diseases 0.000 claims 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010037113 Pseudoaldosteronism Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 206010040744 Sinus headache Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 206010049447 Tachyarrhythmia Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 206010057040 Temperature intolerance Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 206010043994 Tonic convulsion Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000008543 heat sensitivity Effects 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000007004 malignant hyperthermia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- NEBUOXBYNAHKFV-NRFANRHFSA-N O=C1N(Cc2ccc(C(F)(F)F)[o]2)c2ccccc2[C@@]11c(cc2OCOc2c2)c2OC1 Chemical compound O=C1N(Cc2ccc(C(F)(F)F)[o]2)c2ccccc2[C@@]11c(cc2OCOc2c2)c2OC1 NEBUOXBYNAHKFV-NRFANRHFSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22142409P | 2009-06-29 | 2009-06-29 | |
| US61/221,424 | 2009-06-29 | ||
| PCT/US2010/040187 WO2011002708A1 (en) | 2009-06-29 | 2010-06-28 | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014235262A Division JP2015038153A (ja) | 2009-06-29 | 2014-11-20 | スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532107A JP2012532107A (ja) | 2012-12-13 |
| JP2012532107A5 true JP2012532107A5 (enExample) | 2013-08-01 |
Family
ID=42416878
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517823A Withdrawn JP2012532107A (ja) | 2009-06-29 | 2010-06-28 | スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用 |
| JP2014235262A Withdrawn JP2015038153A (ja) | 2009-06-29 | 2014-11-20 | スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用 |
| JP2016198877A Withdrawn JP2017002085A (ja) | 2009-06-29 | 2016-10-07 | スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014235262A Withdrawn JP2015038153A (ja) | 2009-06-29 | 2014-11-20 | スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用 |
| JP2016198877A Withdrawn JP2017002085A (ja) | 2009-06-29 | 2016-10-07 | スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用 |
Country Status (34)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9278088B2 (en) | 2002-02-19 | 2016-03-08 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| MY145694A (en) * | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR063278A1 (es) * | 2006-10-12 | 2009-01-14 | Xenon Pharmaceuticals Inc | Compuestos de espiro-oxindol, una composicion farmaceutica que los comprende y su uso para el tratamiento de enfermedades o condiciones mediadas por los canales de sodio. |
| ATE545416T1 (de) | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| WO2010045197A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN103664973B (zh) * | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| NZ599334A (en) * | 2009-10-14 | 2014-03-28 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| WO2012049555A1 (en) | 2010-10-13 | 2012-04-19 | Lupin Limited | Spirocyclic compounds as voltage-gated sodium channel modulators |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| PL3513793T3 (pl) | 2011-09-02 | 2021-09-20 | Incyte Holdings Corporation | Heterocykloaminy jako inhibitory pi3k |
| EP2638908A1 (en) * | 2012-03-16 | 2013-09-18 | Phytotox SpA | Paralytic Shellfish Poison |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| KR20150002794A (ko) * | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2015138686A (ru) * | 2013-02-13 | 2017-03-17 | Новартис Аг | Анальгетические средства для местного офтальмологического применения |
| TWI703154B (zh) | 2013-12-13 | 2020-09-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之吡啶酮醯胺之前藥 |
| TW201540299A (zh) * | 2014-02-05 | 2015-11-01 | Teva Pharmaceuticals Int Gmbh | 以螺－吲哚酮化合物之局部製劑治療與關節之骨關節炎相關的疼痛之方法 |
| EP3126360A1 (en) | 2014-03-29 | 2017-02-08 | Lupin Limited | Sulfonamide compounds as voltage gated sodium channel modulators |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| RS63963B1 (sr) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corp | Postupak pripreme pi3k inhibitora |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9840513B2 (en) * | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| TW201722938A (zh) | 2015-09-04 | 2017-07-01 | 魯賓有限公司 | 作為電位閘控鈉通道調節子之磺醯胺化合物 |
| EP3390374B1 (en) | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| US10118932B2 (en) | 2016-06-16 | 2018-11-06 | Xenon Pharmaceuticals Inc. | Solid state forms of spiro-oxindole compounds |
| WO2018163077A1 (en) | 2017-03-08 | 2018-09-13 | Lupin Limited | Indanyl compounds as voltage gated sodium channel modulators |
| US11306100B2 (en) | 2017-03-10 | 2022-04-19 | Council Of Scientific & Industrial Research | Spirooxindole compounds as GSK3B inhibitors and process for preparation thereof |
| UA124857C2 (uk) | 2017-05-16 | 2021-12-01 | Вертекс Фармасьютикалз Інкорпорейтед | Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів |
| UY37806A (es) | 2017-07-11 | 2020-01-31 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
| AU2018347349A1 (en) | 2017-10-10 | 2020-04-23 | Biogen Inc. | Process for preparing spiro derivatives |
| EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| AU2019277560B2 (en) | 2018-06-01 | 2025-04-24 | Incyte Corporation | Dosing regimen for the treatment of PI3K related disorders |
| US11993581B2 (en) | 2018-07-09 | 2024-05-28 | Lieber Institue, Inc | Pyridazine compounds for inhibiting Nav1.8 |
| JP2021530478A (ja) | 2018-07-09 | 2021-11-11 | リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. | ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 |
| CN112689636B (zh) | 2018-09-10 | 2024-08-20 | 科研制药株式会社 | 新型杂原子芳香族酰胺衍生物以及含有其的药剂 |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US11162356B2 (en) | 2019-02-05 | 2021-11-02 | Motive Drilling Technologies, Inc. | Downhole display |
| EP3887647B1 (en) | 2019-02-05 | 2024-10-30 | Magnetic Variation Services, LLC | Geosteering methods and systems for improved drilling performance |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| BR112022004293A2 (pt) | 2019-09-09 | 2022-06-21 | Pacira Therapeutics Inc | Géis termofixantes de liberação sustentada compreendendo bloqueadores de canais de sódio e os métodos para fazer o mesmo |
| HUE069128T2 (hu) | 2019-12-06 | 2025-02-28 | Vertex Pharma | Szubsztituált tetrahidrofurán vegyületek mint nátriumcsatornák modulátorai |
| WO2022192427A1 (en) | 2021-03-10 | 2022-09-15 | Pacira Therapeutics, Inc. | Sustained release thermosetting gels comprising sodium channel blockers and the methods of making the same |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| US20240285596A1 (en) | 2021-06-04 | 2024-08-29 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| US20240294512A1 (en) | 2021-06-04 | 2024-09-05 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| RU2763140C1 (ru) * | 2021-06-29 | 2021-12-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | 4-[2-(гидроксиметил)-фениламино]-6',6'-диметил-1'-(2-фторфенил)-3-(4-хлорбензоил)-6',7'-дигидро-5Н-спиро[фуран-2,3'-индол]-2',4',5(1'H,5'H)-трион в качестве средства, обладающего противомикробной активностью |
| CN119522214A (zh) | 2022-04-22 | 2025-02-25 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202404969A (zh) | 2022-04-22 | 2024-02-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| AU2024306684A1 (en) * | 2023-06-28 | 2025-08-07 | Avelos Therapeutics Inc. | Substituted spiro compound derivatives and their pharmaceutical use |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3189617A (en) | 1961-02-03 | 1965-06-15 | Sterling Drug Inc | 1-aryloxindoles and their preparation |
| DE1956237A1 (de) | 1969-11-08 | 1971-05-13 | Basf Ag | Spiro-pyrrolizidon-oxindole |
| DE2113343A1 (de) | 1971-03-19 | 1972-09-21 | Thiemann Chem Pharm Fab | Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung |
| US3723459A (en) | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| CH577461A5 (enExample) | 1975-08-13 | 1976-07-15 | Robins Co Inc A H | |
| US4670566A (en) | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4440785A (en) | 1980-10-30 | 1984-04-03 | A. H. Robins Company, Inc. | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation |
| US4438130A (en) | 1981-11-12 | 1984-03-20 | The Upjohn Company | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds |
| JPS60142984A (ja) | 1983-12-28 | 1985-07-29 | Kyorin Pharmaceut Co Ltd | 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法 |
| US4569942A (en) | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
| JPS6130554A (ja) * | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
| US4690943A (en) | 1984-09-19 | 1987-09-01 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
| US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
| DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
| ES2054860T5 (es) * | 1987-07-17 | 2003-11-01 | Schering Ag | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. |
| US5182289A (en) | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
| CA2037923C (en) | 1989-07-25 | 1996-08-06 | Akihiro Kawaguchi | Oxindole derivative |
| DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5023265A (en) | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
| US5484778C1 (en) | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
| AU648359B2 (en) | 1990-11-22 | 1994-04-21 | Janssen Pharmaceutica N.V. | Isonicotinic acid derivatives |
| US5116854A (en) | 1991-06-28 | 1992-05-26 | Pfizer Inc. | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
| CZ283965B6 (cs) | 1992-08-06 | 1998-07-15 | Warner-Lambert Company | 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi |
| US5278162A (en) | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
| US5296478A (en) | 1992-10-07 | 1994-03-22 | The Dupont Merck Pharmaceutical Co. | 1-substituted oxindoles as cognition enhancers |
| US5776936A (en) | 1992-11-13 | 1998-07-07 | Pharmacia & Upjohn Company | Marcfortine/paraherquamide derivatives useful as antiparasitic agents |
| DE4242451A1 (de) | 1992-12-16 | 1994-06-23 | Basf Ag | Verfahren zur Herstellung von 5-Ringheterocyclen |
| US5298522A (en) | 1993-01-22 | 1994-03-29 | Pfizer Inc. | 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
| AT400950B (de) | 1994-02-04 | 1996-04-25 | Immodal Pharmaka Gmbh | Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen |
| EP0754183A1 (fr) | 1994-04-07 | 1997-01-22 | Cemaf | Nouveaux derives de spiro[indole-pyrrolidine] agonistes melatoninergiques, leur procede de preparation et leur utilisation a titre de medicament |
| FR2722195B1 (fr) | 1994-07-07 | 1996-08-23 | Adir | Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
| NZ298036A (en) | 1994-12-22 | 1998-11-25 | Smithkline Beecham Plc | Tetracyclic spiro compounds and medicaments thereof |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
| CA2235686C (en) | 1995-10-24 | 2007-06-26 | Sanofi | Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them |
| HUP9600855A3 (en) | 1996-04-03 | 1998-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tenidap |
| JPH1095766A (ja) | 1996-09-19 | 1998-04-14 | Sanwa Kagaku Kenkyusho Co Ltd | アセトアミド誘導体、及びその用途 |
| FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
| ATE467418T1 (de) | 1997-01-20 | 2010-05-15 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
| NO317155B1 (no) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| EP1008588B1 (en) * | 1997-02-10 | 2003-04-16 | Ono Pharmaceutical Co., Ltd. | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient |
| ATE227120T1 (de) | 1997-05-07 | 2002-11-15 | Galen Chemicals Ltd | Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen |
| KR20010033538A (ko) * | 1997-12-25 | 2001-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | ω-시클로알킬-프로스타글란딘 Ｅ２ 유도체 |
| JP4087938B2 (ja) * | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
| RO121028B1 (ro) | 1998-04-01 | 2006-11-30 | Nortran Pharmaceuticals Inc. | Compuşi aminociclohexil eteri şi utilizările acestora |
| US20040038970A1 (en) | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
| US6235780B1 (en) * | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| WO2000006556A1 (en) | 1998-07-27 | 2000-02-10 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| KR100666514B1 (ko) | 1999-05-21 | 2007-02-28 | 브리스톨-마이어즈 스퀴브 컴페니 | 키나제의 피롤로트리아진 저해제 |
| CA2378369C (en) | 1999-07-21 | 2007-10-02 | Terence Alfred Kelly | Small molecules useful in the treatment of inflammatory disease |
| CA2378202A1 (en) | 1999-07-21 | 2001-01-25 | Odd-Geir Berge | New compounds |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| AU1846501A (en) | 1999-11-26 | 2001-06-04 | Bionomics Limited | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| AU2002213204A1 (en) | 2000-10-13 | 2002-04-22 | Bristol-Myers Squibb Company | Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| JP2004513164A (ja) | 2000-11-10 | 2004-04-30 | イーライ・リリー・アンド・カンパニー | ３−置換オキシインドールβ３アゴニスト |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US20030078278A1 (en) | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
| ES2262817T3 (es) | 2001-08-14 | 2006-12-01 | Eli Lilly And Company | Agonistas beta-3 oxindol 3-sustituidos. |
| EP1451173A4 (en) | 2001-11-01 | 2005-10-26 | Icagen Inc | PIPERIDINE |
| EP1451160B1 (en) | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
| DE60204718T2 (de) | 2001-11-20 | 2006-05-18 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol beta 3 agonisten |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| WO2003064425A1 (en) | 2002-01-28 | 2003-08-07 | Pfizer Japan Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| AU2003230581A1 (en) | 2002-03-15 | 2003-09-29 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
| AU2003258952A1 (en) | 2002-06-25 | 2004-01-06 | Wyeth | Use of thio-oxindole derivatives in treatment of skin disorders |
| CA2489813A1 (en) | 2002-06-25 | 2003-12-31 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| US7256218B2 (en) | 2002-11-22 | 2007-08-14 | Jacobus Pharmaceutical Company, Inc. | Biguanide and dihydrotriazine derivatives |
| KR20120102571A (ko) | 2003-02-24 | 2012-09-18 | 미쓰비시 타나베 파마 코퍼레이션 | 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도 |
| CA2625837A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
| JP2007502856A (ja) | 2003-05-16 | 2007-02-15 | ファイザー・プロダクツ・インク | 精神病性障害および抑うつ性障害の治療 |
| JP2007522095A (ja) | 2003-05-16 | 2007-08-09 | ファイザー・プロダクツ・インク | ジプラシドンを用いた不安の治療 |
| BRPI0410222A (pt) | 2003-05-16 | 2006-05-09 | Pfizer Prod Inc | tratamento de distúrbios bipolares e sintomas associados |
| SG145701A1 (en) | 2003-07-30 | 2008-09-29 | Xenon Pharmaceuticals Inc | Piperazine derivatives and their use as therapeutic agents |
| DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
| WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| JPWO2005035498A1 (ja) | 2003-10-08 | 2006-12-21 | 住友製薬株式会社 | 含窒素二環性化合物の摂食調節剤としての用途 |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
| GB0406867D0 (en) | 2004-03-26 | 2004-04-28 | F2G Ltd | Antifungal agents |
| AU2005231332A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
| BRPI0509377A (pt) | 2004-03-29 | 2007-09-11 | Pfizer | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 |
| GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| WO2005099689A1 (en) | 2004-04-01 | 2005-10-27 | Case Western Reserve University | Topical delivery of phthalocyanines |
| CN1953747A (zh) | 2004-04-08 | 2007-04-25 | 顶标公司 | 二苯基－吲哚－2－酮化合物及其在治疗癌症中的用途 |
| CA2563063C (en) | 2004-04-27 | 2014-06-03 | Wyeth | Purification of progesterone receptor modulators |
| CA2555718A1 (en) | 2004-05-05 | 2005-11-10 | Unibioscreen S.A. | Naphthalimide derivatives for the treatment of cancer |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| WO2005111024A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| AU2005267331A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| JP4677323B2 (ja) | 2004-11-01 | 2011-04-27 | キヤノン株式会社 | 画像処理装置及び画像処理方法 |
| CN101103016A (zh) | 2004-11-18 | 2008-01-09 | 因塞特公司 | 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法 |
| DE102005007694A1 (de) | 2005-02-18 | 2006-09-21 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| WO2006091646A2 (en) | 2005-02-22 | 2006-08-31 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| MX2007013450A (es) | 2005-04-29 | 2008-01-21 | Wyeth Corp | Procedimniento de preparacion de oxindoles y tio-oxindoles 3,3-disustituidos. |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| WO2007025925A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| AU2007258675A1 (en) | 2006-06-09 | 2007-12-21 | Merck Sharp & Dohme Corp. | Benzazepinones as sodium channel blockers |
| WO2008046065A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
| AR063278A1 (es) | 2006-10-12 | 2009-01-14 | Xenon Pharmaceuticals Inc | Compuestos de espiro-oxindol, una composicion farmaceutica que los comprende y su uso para el tratamiento de enfermedades o condiciones mediadas por los canales de sodio. |
| WO2008046087A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| AU2007307635A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| ATE545416T1 (de) | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| WO2008046084A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| GB0704846D0 (en) | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| CA2689137C (en) * | 2007-05-29 | 2017-05-02 | Intrexon Corporation | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN103664973B (zh) | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| WO2010053998A1 (en) | 2008-11-05 | 2010-05-14 | Xenon Pharmaceuticals, Inc. | Spiro-condensed indole derivatives as sodium channel inhibitors |
| WO2010078307A1 (en) | 2008-12-29 | 2010-07-08 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
| WO2010132352A2 (en) | 2009-05-11 | 2010-11-18 | Xenon Pharmaceuticals Inc. | Spiro compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| NZ599334A (en) * | 2009-10-14 | 2014-03-28 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| KR20150002794A (ko) | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
-
2010
- 2010-06-25 AR ARP100102282A patent/AR077252A1/es unknown
- 2010-06-28 PH PH1/2011/502619A patent/PH12011502619A1/en unknown
- 2010-06-28 ES ES10731662.2T patent/ES2578779T3/es active Active
- 2010-06-28 NZ NZ596903A patent/NZ596903A/en unknown
- 2010-06-28 RU RU2012102896/04A patent/RU2535667C2/ru not_active IP Right Cessation
- 2010-06-28 PL PL14000690T patent/PL2789617T3/pl unknown
- 2010-06-28 HR HRP20160732TT patent/HRP20160732T1/hr unknown
- 2010-06-28 BR BRPI1012129A patent/BRPI1012129A2/pt not_active IP Right Cessation
- 2010-06-28 CN CN201510007582.0A patent/CN104650106A/zh active Pending
- 2010-06-28 HU HUE10731662A patent/HUE029658T2/en unknown
- 2010-06-28 CA CA2764878A patent/CA2764878C/en active Active
- 2010-06-28 PE PE2015002585A patent/PE20160216A1/es not_active Application Discontinuation
- 2010-06-28 CN CN201080029572.2A patent/CN102471347B/zh active Active
- 2010-06-28 AU AU2010266549A patent/AU2010266549B2/en active Active
- 2010-06-28 PL PL10731662.2T patent/PL2448943T3/pl unknown
- 2010-06-28 MX MX2013008427A patent/MX342298B/es unknown
- 2010-06-28 ES ES14000690.9T patent/ES2600160T3/es active Active
- 2010-06-28 MY MYPI2011006363A patent/MY159099A/en unknown
- 2010-06-28 EP EP16001748.9A patent/EP3156407A1/en not_active Withdrawn
- 2010-06-28 DK DK10731662.2T patent/DK2448943T3/en active
- 2010-06-28 WO PCT/US2010/040187 patent/WO2011002708A1/en not_active Ceased
- 2010-06-28 EP EP14000690.9A patent/EP2789617B1/en active Active
- 2010-06-28 MX MX2012000028A patent/MX2012000028A/es active IP Right Grant
- 2010-06-28 JP JP2012517823A patent/JP2012532107A/ja not_active Withdrawn
- 2010-06-28 US US12/825,168 patent/US8450358B2/en active Active
- 2010-06-28 EP EP10731662.2A patent/EP2448943B1/en active Active
- 2010-06-28 SG SG2011090081A patent/SG176307A1/en unknown
- 2010-06-28 KR KR1020117031238A patent/KR101751378B1/ko not_active Expired - Fee Related
- 2010-06-28 PT PT107316622T patent/PT2448943T/pt unknown
- 2010-06-28 SI SI201031198A patent/SI2448943T1/sl unknown
- 2010-06-28 HR HR20110946A patent/HRP20110946A2/hr not_active Application Discontinuation
- 2010-06-28 PE PE2011002098A patent/PE20120413A1/es not_active Application Discontinuation
- 2010-06-29 TW TW099121292A patent/TWI465452B/zh not_active IP Right Cessation
-
2011
- 2011-12-06 CO CO11168005A patent/CO6470866A2/es not_active Application Discontinuation
- 2011-12-06 ZA ZA2011/08960A patent/ZA201108960B/en unknown
- 2011-12-09 EC EC2011011512A patent/ECSP11011512A/es unknown
- 2011-12-16 MA MA34459A patent/MA33552B1/fr unknown
- 2011-12-23 TN TNP2011000664A patent/TN2011000664A1/en unknown
- 2011-12-28 CL CL2011003335A patent/CL2011003335A1/es unknown
- 2011-12-29 IL IL217285A patent/IL217285A/en not_active IP Right Cessation
-
2012
- 2012-09-14 US US13/619,915 patent/US8883840B2/en not_active Expired - Fee Related
-
2014
- 2014-10-09 US US14/510,634 patent/US9480677B2/en not_active Expired - Fee Related
- 2014-11-20 JP JP2014235262A patent/JP2015038153A/ja not_active Withdrawn
-
2015
- 2015-10-07 PH PH12015502323A patent/PH12015502323A1/en unknown
- 2015-10-08 IL IL241985A patent/IL241985A/en not_active IP Right Cessation
-
2016
- 2016-06-28 CY CY20161100581T patent/CY1117776T1/el unknown
- 2016-06-29 SM SM201600203T patent/SMT201600203B/it unknown
- 2016-09-28 US US15/278,759 patent/US20170073351A1/en not_active Abandoned
- 2016-10-07 JP JP2016198877A patent/JP2017002085A/ja not_active Withdrawn
-
2017
- 2017-01-26 IL IL250314A patent/IL250314A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532107A5 (enExample) | ||
| US10829461B2 (en) | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | |
| RU2012102896A (ru) | Энантиомеры спиро-оксиндольных соединений и их применение в качестве терапевтических средств | |
| KR102388440B1 (ko) | 헤테로시클릭 화합물 | |
| JP6964096B2 (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| JP2008535916A5 (enExample) | ||
| RU2007141633A (ru) | Спирогетероциклические соединения и их применение в качестве терапевтических средств | |
| JP2009511498A5 (enExample) | ||
| JP2009530237A (ja) | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 | |
| EP2303895B1 (en) | Thiazolyl- and oxazolyl-isoquinolinones and methods for using them | |
| CN110372703A (zh) | 五元杂环并嘧啶类化合物及其用途 | |
| WO2014021337A1 (ja) | 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 | |
| KR101494919B1 (ko) | 2환식 복소환 화합물 | |
| JP2013536207A (ja) | ヒドロキサメート骨格のデアセチラーゼ類阻害剤 | |
| CN107667097B (zh) | 3-乙基双环[3.2.0]庚-3-烯-6-酮的对映体的分离 | |
| JP2009523806A5 (enExample) | ||
| JP2013541588A5 (enExample) | ||
| WO2023177351A1 (en) | Nf қb inducing kinase inhibitors and methods thereof | |
| RS61908B1 (sr) | Postupak za proizvodnju kondenzovanih imidazolo derivata | |
| JPWO2023025277A5 (enExample) |